Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Decline in Short Interest

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 116,763 shares, a decline of 12.6% from the February 12th total of 133,525 shares. Based on an average trading volume of 20,886 shares, the days-to-cover ratio is presently 5.6 days. Currently, 11.7% of the company’s shares are sold short. Currently, 11.7% of the company’s shares are sold short. Based on an average trading volume of 20,886 shares, the days-to-cover ratio is presently 5.6 days.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on APVO shares. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $4.63 on Wednesday. The business’s 50 day moving average price is $7.28 and its 200-day moving average price is $18.22. Aptevo Therapeutics has a 1 year low of $3.95 and a 1 year high of $1,299.60. The firm has a market capitalization of $4.62 million, a price-to-earnings ratio of 0.00 and a beta of 1.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Birchview Capital LP acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned approximately 1.32% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.